Cerebral cavernous malformations (CCMs) are vascular malformations which may occur in familial forms which have autosomal dominant inheritance. Mutations have been identified in three genes: KRIT1, MGC4607 and PDCD10. We have documented a novel mutation on KRIT1 gene, and the second to be reported in a Portuguese family. This mutation consists in a two nucleotide insertion (c.947_948insAC) within the exon 10, resulting in premature protein termination (p.Leu317Argfs*2). These findings will hopefully contribute to a better clinical, imaging and genetic characterisation of this disease, particularly while trying to identify the factors that influence its treatment and prognosis.
Introduction
Cerebral cavernous malformations (CCMs) are vascular malformations consisting of abnormally dilated capillary cavities, covered by a single layer of endothelium, with no involvement of brain parenchyma [1, 2] . They have an estimated prevalence of 0,4-0,9% in the general population, based on magnetic resonance imaging (MRI) and postmortem studies [1, 2] .
MRI is the method of choice for the diagnosis of CCMs. In T2-weighted images, they appear as "popcorn-like" lesions with a mixed signal intensity core, usually surrounded by a hypointense hemosiderin rim. The T2*-weighted gradient-echo (GRE) and susceptibility-weighted imaging sequences are considered the most sensitive and are of particular importance in identifying multiple CCMs [2, 3] .
CCMs may arise in sporadic or familial forms, the latter being defined by its occurrence in at least two family members, usually with multiple lesions [3] Familial forms have autosomal dominant inheritance with incomplete penetrance, wherein mutations were identified in three genes: KRIT1/CCM1, MGC4607/CCM2 and PDCD10/CCM3. The KRIT1 gene is altered in about 40% of the familial cases, resulting in loss of function of the homonymous protein. KRIT1 protein is a central regulator of angiogenesis, endothelial proliferation, and maintenance of blood vessel structural integrity [3] .
To date, only one Portuguese case of familial CCMs (fCCM) has been reported in the literature [4] . Here we describe two family members affected by CCMs due to a novel mutation in KRIT1 gene.
Case report

Patient 1
A 31-year-old previously healthy female presented with a three years' duration epileptic disorder, with focal seizures with impaired awareness accompanied by bimanual and oromandibular automatisms, and ictal speech, followed by postictal confusion and euphoria. Seizures had a weekly frequency and occured in clusters. General and neurological examinations were normal. The electroencephalogram (EEG) documented focal right temporal lobe epileptiform activity. Subsequent MRI evaluation revealed multiple (approximately fifteen) bilateral cerebellar and cerebral hemispheric cavernous malformations, and one cervical spinal cord lesion (Fig. 1) . Seizure control was transiently achieved with levetiracetam 3000 mg daily and zonisamide 400 mg daily. Nonetheless, even with the subsequent addition of eslicarbazepine, the condition evolved into pharmacoresistant epilepsy. The patient is currently undergoing presurgical evaluation.
Patient 2
The proband's 50-year-old mother was found to have a history of focal to bilateral tonic-clonic seizures, initiated at age 13, that remained controlled until she turned 21 years of age, when seizures became increasingly frequent. She underwent surgical excision of a cortical cavernoma at age 27 and was subsequently seizure-and medication-free for eight years. Seizures recurred at age 35, characterized by an epigastric aura, oromandibular automatisms, and right upper limb dystonic posturing. Her neurological examination was unremarkable except for a right Babinski sign. Routine EEG was normal and Brain MRI showed numerous bilateral supra-and infratentorial CCMs (Fig. 2) . Seizures were subsequently controlled with carbamazepine.
Further family history revealed that the proband's mother had a maternal half-sister who also had epilepsy since her adolescence (Fig. 3) . She had undergone surgical removal of a cortical cavernoma during her adulthood but was never seizure-free. The proband had two younger maternal half-brothers, aged 28 and 14 years, who were asymptomatic. Unfortunately, none of these family members could be contacted and investigated for the presence of CCMs.
Given the clinical and imaging features of both the proband and her mother, we investigated the patients for familial forms of cerebral cavernomas. Genetic testing was performed on genomic DNA extracted from the patients' peripheral blood, by sequencing (using Sanger sequencing method; transcript number NM_194456.1) the full coding region of the KRIT1 gene as well as the exon-intron boundaries. The molecular analysis identified the same KRIT1 gene heterozygous mutation in both patients, consistent with the diagnosis of Hereditary CCM type 1 and showing autosomal dominant inheritance. This mutation consists in a two nucleotide insertion (c.947_948insAC) within the exon 10, resulting in premature protein termination (p.Leu317Argfs*2). To our knowledge, this insertion mutation was not yet reported in the literature and in population databases (ESP and ExAC).
Discussion
CCMs are dynamic lesions that tend to increase in number and size over the years, particularly in familial cases [1] . The detection of multiple CCMs raises the possibility of an inherited disease and the need for a familial diagnostic workup. The diagnosis of fCCMs is established when there are at least two affected family members and/or a heterozygous pathogenic variant in KRIT1, CCM2, or PDCD10 genes is detected [3] .
In general, fCCMs have an indolent course, and up to half of the patients remain asymptomatic throughout their lives. Management is primarily conservative, and treatment is symptomatic [1, 3] . Seizures are the most frequent manifestation, and given the high risk of recurrence after a first seizure, antiepileptic (AE) drug treatment is mandatory. Nonetheless, cavernoma-related epilepsy is often drug-resistant [2] . In patients with multiple lesions, surgical treatment should only be considered for clinically significant haemorrhage, progressive neurological deficits and refractory seizures [1, 3] . Surgery has had promising results in patients with multiple CCMs and a single epileptogenic focus, keeping in mind that, according to recommendations of the International League Against Epilepsy, an early referral is strongly indicated [2] . There are no guidelines regarding a second surgical procedure in the event of seizure recurrence. Prophylactic surgery is not recommended in asymptomatic lesions [1, 3] .
Several drugs targeting pathways which regulate cavernoma proliferation are currently under investigation (in vitro and in animal models) [3] .
Patients with fCCM require a careful follow-up. Anticoagulants and other medications that increase the risk of haemorrhage should be avoided when possible, as supported by limited evidence from single-case reports [1, 3] . Brain MRI must be repeated in the event of significant clinical changes or new neurological symptoms. Some studies advise a periodic imaging monitoring for symptomatic individuals [3] . There are no definitive recommendations regarding the follow-up of asymptomatic patients or relatives. Genetic counselling, including the discussion of reproductive options, should be offered to affected young adults. Prenatal testing is possible if the pathogenic variant has been previously identified in the family [3] .
Conclusion
We have documented a novel mutation on KRIT1 gene and the second to be reported in the Portuguese population [4] , where the genetics of fCCMs remains mostly unknown. These findings will hopefully contribute to a better clinical, imaging and genetic characterisation of this disease, particularly while trying to identify the factors that influence its treatment and prognosis.
